Read Part I of my story at http://blog.mountsinai.org/blog/hepatitisc-treatment
My name is Andrew Styles. Hepatitis C is a liver infection caused by a virus. Hepatitis means inflammation of the liver, an organ that carries out over 500 functions that keep you healthy. I just successfully completed a new treatment for Hepatitis C (Hep C) and want to inspire others to get tested and treated. I was treated in the past with serious side effects, but this time was different. On the new treatment, the only symptom I got was mild fatigue. The new medicine in my treatment, Sofosbuvir (SOVALDI), was approved by the FDA on December 6, 2013, for treatment and cure of Hepatitis C virus. There are different treatments available and the treatment depends on your genotype (which kind of Hep C virus you have), your stage of liver disease and your other health issues. The full treatment that I just completed was Sofosbuvir (SOVALDI) 400 mg tablet once daily taken with a combination of Ribavirin 600 mg tablet 2 times a day and Peginterferon alfa-2a (PEGRASYS PROCLICK) 180 mcg/0.5 ml., a once a week injection.
A new therapeutic clinical trial is now available at Mount Sinai for patients with HPV-related oropharyngeal (tonsil and tongue base) cancer who are eligible to undergo robot-assisted surgery. This study tests a novel vaccine (ADXS11-001) that patients receive during a specific window prior to undergoing surgery.
“Instead of offering traditional surgery and radiation, we are offering a newer vaccine approach to try to fight the virus, which is the actual cause of the cancer, versus chasing it on the back side with radiation and surgery,“ says Brett Miles, DDS, MD, the surgical oncologist and co-investigator on the trial.
The vaccine uses a novel principle to stimulate the immune system. Most of the available HPV vaccines to date have been preventive vaccines that do not treat patients who have already been affected with the virus. The vaccine in this trial uses a therapeutic approach, which can be used in patients who already have HPV-related cancer.
For more information:
Icahn School of Medicine at Mount Sinai has received a $3.8 million grant from the American Heart Association (AHA) to promote cardiovascular health through early education and intervention programs targeting high-risk children and their parents in Harlem and the Bronx.
Mount Sinai researchers will study the genes and lifestyles of 600 preschoolers and their parents or guardians who live in these communities, which are associated with high rates of obesity, cardiovascular disease, stroke, and type 2 diabetes. The investigators will track whether the interventions lead to healthier eating habits and additional exercise. They will also examine the participants’ DNA and RNA to understand how genetics plays a role in the development of cardiovascular disease.
Pediatric patients and their families recently joined artist and designer Edin Rudic in creating a new interior wall design for the Food for Life program in the Mount Sinai Health System’s Clinic for Inherited Metabolic Diseases. Mr. Rudic donated his services to create the new design located in the reception area of the Medical Genetics Clinic. It incorporates a high-definition screen display of patient photos, and specially coated walls on which children can draw, adding fun to their hospital visits.
A long-standing belief that mammals use the same potent antiviral molecules deployed by plants and invertebrates is being challenged by researchers at Icahn School of Medicine at Mount Sinai.
Their findings, published in the July 10, 2014, issue of Cell Reports, surprised many scientists who assumed that antiviral RNA Interference (RNAi) exists in humans as a natural result of evolution.
Scientists know that human cells, like cells in every living organism with a nucleus, encode and generate small RNAs, which influence our genetics. It is also known that mammals combat viruses with interferons—proteins manufactured by immune cells in response to pathogens.
A young woman who underwent a high-stakes liver transplant at The Mount Sinai Hospital in May is now safely back home thanks to an extraordinary collaboration between Stephan Mayer, MD, Director of the Institute for Critical Care Medicine, and Sander Florman, MD, Charles Miller, MD, Professor of Surgery and Director of the Recanati/Miller Transplantation Institute, and their teams.
On May 21, 13 students, left, from the Urban Assembly School for Law and Justice (SLJ), grades 9 through 12, met with Lisa Eiland, MD, (far left) and Shana Dacon, Program Manager, Office for Diversity and Inclusion (ODI), (far right) for an afternoon tour of Mount Sinai Roosevelt. Read more
Sweating it out on the court day after day is a great way to become a better tennis player, but don’t forget that one of the most essential components of your training happens off the court. Proper nutrition is often the missing link needed to help maximize your training and reach performance goals. Fuel up on these six super foods and gear up for a great season!
It’s summer (finally!), and there’s nothing better than some quality playing-time in beautiful weather. But, with the mercury rising, dehydration is a serious concern whether you’re having a marathon practice session or match, and can affect performance when as little as 2% of your body mass is lost through sweat. Since tennis players can lose more than 2.5 liters of sweat per hour in warm weather, it’s easy to fall behind on your fluid intake if you’re not careful.
With summer now in full swing, many of us will be out running, trying our best at soccer to support the World Cup and gearing up our tennis skills with the French and US Open upon us. But since many of us are not pros, we may succumb to plantar fasciitis.
Plantar fasciitis (PF) is the most common cause of foot pain, and odds are if you’re active in exercise or an athlete, you probably have suffered through it. It’s characterized by inflammation of the tendons and muscles of the foot and calf where they insert on your heel, and is usually burning and sharp in sensation and worst with walking when you wake in the morning. You are at risk if you have flat feet, a leg length discrepancy, stand for long periods of time on hard surfaces, and are overweight.